Search Results for "Brilinta Sales"

02:22 EDT 2nd September 2015 | BioPortfolio

Matching Channels

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Sales Jobs

Boehringer Ingelheim

<!--LGfEGNT2Lhm-->Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales.&...

OxyContin

OxyContin, an narcotic <!--LGfEGNT2Lhm-->analgesic produced by Purdue Pharma LP, nets $3m in <!--LGfEGNT2Lhm-->sales annually, placing it 8th in the world for annual sales. OxyContin i...

GE Healthcare

Ranked as the third largest medical device company in the world (based on annual sales), GE Healthcare generates $16 billion in sales each year. GEs' area of expertise is the imaging that is i...

Matching News

Importance of continued Brilinta treatment beyond one year of a heart attack

A sub-analysis of the PEGASUS-TIMI 54 study, assessing the effect of Brilinta (ticagrelor) in reducing…

Mixed results for AstraZeneca in high-profile Brilinta study

Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it showed mixed results in a post heart attack trial. A large outc...

AZ unveils Brilinta data, seeks label extension

AstraZeneca plc (LSE:AZN; NYSE:AZN) revealed new details from a 21,000-patient CV outcomes study showing that long-term use of the anticoagulant Brilinta ticagrelor reduced the incidence of major thro...

ACC 2015: AstraZeneca optimistic on Brilinta after PEGASUS, others less so

AstraZeneca's US president Paul Hudson is optimistic about the opportunities for Brilinta (ticagrelor) in longer-term treatment of acute coronary syndrome (ACS) based on results from the Phase III PEG...

FDA Approves New Crushing Option for the Administration of Brilinta

March 30, 2015 -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are una...

AstraZeneca: FDA Approves New Administration Option For BRILINTA

LONDON (dpa-AFX) - AstraZeneca (AZN) announced the US FDA has approved a new administration option for acute coronary syndrome patients who are unable to swallow BRILINTA 90 mg tablets whole. The ...

Brintellix (vortioxetine) and Brilinta (ticagrelor): Drug Safety Communication - Name Confusion

Audience: Pharmacy, Cardiology, Psychiatry [Posted 07/30/2015] ISSUE: FDA is warning health care professionals and patients that reports of confusion between the antidepressant Brintellix and anti-bl...

AstraZeneca's Brilinta gets FDA priority review for potential new indication

The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted priority review for AstraZeneca's Brilinta (ticagrelor) tablets for patients with a histor...

Matching PubMed Articles

Sales promotion strategies and youth drinking in Australia.

This study employed an exploratory approach to generate detailed information about how in-store shopping experiences and exposure to sales promotion activities feature in the alcohol choices of Austra...

The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study.

Prescription drug sales may vary considerably across regions and over time. This study aimed to assess whether there is an association between mean drug sales and prevalence of excessive use in a rang...

Is local alcohol outlet density related to alcohol-related morbidity and mortality in Scottish cities?

Alcohol consumption may be influenced by the local alcohol retailing environment. This study is the first to examine neighbourhood alcohol outlet availability (on- and off-sales outlets) and alcohol-r...

Evaluation of concentrations of pharmaceuticals detected in sewage influents in Japan by using annual shipping and sales data.

A year-round monitoring survey of sewage flowing into sewage treatment plants located in urban Japan was conducted by targeting seven representative pharmaceutical components-atenolol (ATL), ciproflox...

Community reductions in youth smoking after raising the minimum tobacco sales age to 21.

Raising the tobacco sales age to 21 has gained support as a promising strategy to reduce youth cigarette access, but there is little direct evidence of its impact on adolescent smoking. Using regional...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement